Clinical outcome of 27 imatinib mesylate-resistant chronic myelogenous leukemia patients harboring a T315I BCR-ABL mutation
Copyright policy )Clinical outcome of 27 imatinib mesylate-resistant chronic myelogenous leukemia patients harboring a T315I BCR-ABL mutation
We analyzed 27 CML patients treated with imatinib (IM) who developed a BCR-ABLT315I mutation. These patients had poor prognostic features: High or intermediate Sokal index (82%), and lack of CCyR under IM (59%). At T315I discovery, patients were in advanced phase (59%), with clonal evolution (84%). Median time since diagnosis was 39 months, and progression occurred 13 months after IM initiation, regardless of disease phase. Overall survival since IM initiation was 42.5 months for chronic, and 17.5 months for advanced phases, and all patients progressed. This mutation seems related to or (partially?) responsible for progression and poor survival.
Adult, Male, Fusion Proteins, bcr-abl, Antineoplastic Agents, Middle Aged, Protein-Tyrosine Kinases, Piperazines, Pyrimidines, Drug Resistance, Neoplasm, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Benzamides, Mutation, Imatinib Mesylate, Humans, Diseases of the blood and blood-forming organs, Female, RC633-647.5, Aged, Retrospective Studies
Adult, Male, Fusion Proteins, bcr-abl, Antineoplastic Agents, Middle Aged, Protein-Tyrosine Kinases, Piperazines, Pyrimidines, Drug Resistance, Neoplasm, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Benzamides, Mutation, Imatinib Mesylate, Humans, Diseases of the blood and blood-forming organs, Female, RC633-647.5, Aged, Retrospective Studies
citations This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).61 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Top 10% influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Top 10% impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Top 10%
Citations provided by BIP!Popularity provided by BIP!